Anaplastic lymphoma kinase inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 72 Hours
DelveInsight’s, “Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Anaplastic Lymphoma Kinase (ALK) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Anaplastic Lymphoma Kinase (ALK) Inhibitors: Overview
The anaplastic lymphoma kinase (ALK) receptor is a membrane-bound tyrosine kinase. The pathogenesis of several cancers is closely related to aberrant forms of ALK or aberrant ALK expression, including ALK fusion proteins, ALK-activated point mutations, and ALK amplification. Clinical applications of different ALK inhibitors represent significant progress in targeted therapy.
Function - The receptor ALK plays a pivotal role in cellular communication and in the normal development and function of the nervous system. This observation is based on the extensive expression of ALK messenger RNA (mRNA) throughout the nervous system during mouse embryogenesis. In vitro functional studies have demonstrated that ALK activation promotes neuronal differentiation of PC12 or neuroblastoma cell lines.
Anaplastic Lymphoma Kinase (ALK) Inhibitors - ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. They fall under the category of tyrosine kinase inhibitors, which work by inhibiting proteins involved in the abnormal growth of tumour cells. All the current approved ALK inhibitors function by binding to the ATP pocket of the abnormal ALK protein, blocking its access to energy and deactivating it. A majority of ALK-rearranged NSCLC harbour the EML4-ALK fusion.
Anaplastic Lymphoma Kinase (ALK) Inhibitors Emerging Drugs Chapters
This segment of the Anaplastic Lymphoma Kinase (ALK) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anaplastic Lymphoma Kinase (ALK) Inhibitors Emerging Drugs
Further product details are provided in the report……..
Anaplastic Lymphoma Kinase (ALK) Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Anaplastic Lymphoma Kinase (ALK) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Anaplastic Lymphoma Kinase (ALK) Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anaplastic Lymphoma Kinase (ALK) Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anaplastic Lymphoma Kinase (ALK) Inhibitors drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Anaplastic Lymphoma Kinase (ALK) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Anaplastic Lymphoma Kinase (ALK) Inhibitors: Overview
The anaplastic lymphoma kinase (ALK) receptor is a membrane-bound tyrosine kinase. The pathogenesis of several cancers is closely related to aberrant forms of ALK or aberrant ALK expression, including ALK fusion proteins, ALK-activated point mutations, and ALK amplification. Clinical applications of different ALK inhibitors represent significant progress in targeted therapy.
Function - The receptor ALK plays a pivotal role in cellular communication and in the normal development and function of the nervous system. This observation is based on the extensive expression of ALK messenger RNA (mRNA) throughout the nervous system during mouse embryogenesis. In vitro functional studies have demonstrated that ALK activation promotes neuronal differentiation of PC12 or neuroblastoma cell lines.
Anaplastic Lymphoma Kinase (ALK) Inhibitors - ALK inhibitors are anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation. They fall under the category of tyrosine kinase inhibitors, which work by inhibiting proteins involved in the abnormal growth of tumour cells. All the current approved ALK inhibitors function by binding to the ATP pocket of the abnormal ALK protein, blocking its access to energy and deactivating it. A majority of ALK-rearranged NSCLC harbour the EML4-ALK fusion.
Anaplastic Lymphoma Kinase (ALK) Inhibitors Emerging Drugs Chapters
This segment of the Anaplastic Lymphoma Kinase (ALK) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anaplastic Lymphoma Kinase (ALK) Inhibitors Emerging Drugs
- Ensartinib: Betta Pharmaceuticals
- TPX 0131: Turning Point Therapeutics
Further product details are provided in the report……..
Anaplastic Lymphoma Kinase (ALK) Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Anaplastic Lymphoma Kinase (ALK) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Anaplastic Lymphoma Kinase (ALK) Inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Anaplastic Lymphoma Kinase (ALK) Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anaplastic Lymphoma Kinase (ALK) Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anaplastic Lymphoma Kinase (ALK) Inhibitors drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Anaplastic Lymphoma Kinase (ALK) Inhibitors R&D. The therapies under development are focused on novel approaches for Anaplastic Lymphoma Kinase (ALK) Inhibitors.
- Anaplastic Lymphoma Kinase (ALK) Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Anaplastic Lymphoma Kinase (ALK) Inhibitors drugs?
- How many Anaplastic Lymphoma Kinase (ALK) Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Anaplastic Lymphoma Kinase (ALK) Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anaplastic Lymphoma Kinase (ALK) Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Anaplastic Lymphoma Kinase (ALK) Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Betta Pharmaceuticals
- Turning Point Therapeutics
- Nuvalent
- Roche
- LegoChem Biosciences
- Pfizer
- Qilu Pharmaceutical
- Ascentage Pharma
- Suzhou Zelgen Biopharmaceuticals
- Chia Tai Tianqing Pharmaceutical Group
- Beijing Pearl Biotechnology
- Novartis
- Ensartinib
- TPX 0131
- NVL 655
- Alectinib
- RF A089
- Lorlatinib
- WX 0593
- APG 2449
- Crizotinib
- Alkotinib
- TQ-B3139
- PLB1003
- Ceritinib
Introduction
Executive Summary
Anaplastic Lymphoma Kinase (ALK) Inhibitors: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Anaplastic Lymphoma Kinase (ALK) Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Anaplastic Lymphoma Kinase (ALK) Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Anaplastic Lymphoma Kinase (ALK) Inhibitors Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Ensartinib: Betta Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
• Comparative Analysis
TPX 0131: Turning Point Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
BI-1701963: Boehringer Ingelheim
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
MRTX-1133: Mirati Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Anaplastic Lymphoma Kinase (ALK) Inhibitors Key Companies
Anaplastic Lymphoma Kinase (ALK) Inhibitors Key Products
Anaplastic Lymphoma Kinase (ALK) Inhibitors- Unmet Needs
Anaplastic Lymphoma Kinase (ALK) Inhibitors- Market Drivers and Barriers
Anaplastic Lymphoma Kinase (ALK) Inhibitors- Future Perspectives and Conclusion
Anaplastic Lymphoma Kinase (ALK) Inhibitors Analyst Views
Anaplastic Lymphoma Kinase (ALK) Inhibitors Key Companies
Appendix
Executive Summary
Anaplastic Lymphoma Kinase (ALK) Inhibitors: Overview
• Structure
• Mechanism of Action
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Anaplastic Lymphoma Kinase (ALK) Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Anaplastic Lymphoma Kinase (ALK) Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Anaplastic Lymphoma Kinase (ALK) Inhibitors Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Ensartinib: Betta Pharmaceuticals
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
• Comparative Analysis
TPX 0131: Turning Point Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
BI-1701963: Boehringer Ingelheim
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
MRTX-1133: Mirati Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Anaplastic Lymphoma Kinase (ALK) Inhibitors Key Companies
Anaplastic Lymphoma Kinase (ALK) Inhibitors Key Products
Anaplastic Lymphoma Kinase (ALK) Inhibitors- Unmet Needs
Anaplastic Lymphoma Kinase (ALK) Inhibitors- Market Drivers and Barriers
Anaplastic Lymphoma Kinase (ALK) Inhibitors- Future Perspectives and Conclusion
Anaplastic Lymphoma Kinase (ALK) Inhibitors Analyst Views
Anaplastic Lymphoma Kinase (ALK) Inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Anaplastic lymphoma kinase inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Anaplastic lymphoma kinase inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Anaplastic lymphoma kinase inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Anaplastic lymphoma kinase inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
